Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology and Infertility, Johns Hopkins University, Lutherville, Maryland.
Department of Population, Family and Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Fertil Steril. 2016 Sep 1;106(3):666-72. doi: 10.1016/j.fertnstert.2016.05.019. Epub 2016 Jun 16.
To evaluate the association between different ovarian hyperstimulation protocols and ectopic pregnancy (EP) in in vitro fertilization (IVF) cycles in fresh autologous embryo transfer cycles in the United States between 2008 and 2011 as reported to the Society of Assisted Reproductive Technology (SART).
Historical cohort study.
Not applicable.
PATIENT(S): None.
INTERVENTION(S): None.
MAIN OUTCOME MEASURE(S): All autologous cycles that resulted in a clinical pregnancy after a fresh, intrauterine embryo transfer and described characteristics of cycles according to protocol were included: luteal GnRH agonist, GnRH agonist flare, or GnRH antagonist. Multivariate logistic regression was conducted to investigate the association between type of protocol and EP.
RESULT(S): Among 136,605 clinical pregnancies, 2,645 (1.94%) were EP. Ectopic pregnancy was more frequent with GnRH antagonist (2.4%) cycles than with GnRH agonist flare (2.1%) or luteal GnRH agonist (1.6%) cycles. After adjusting for maternal and treatment characteristics, the GnRH antagonist and the GnRH agonist flare protocols were associated with increased odds of EP (adjusted odds ratio [aOR] 1.52; 95% confidence interval [CI], 1.39-1.65; and aOR 1.25; 95% CI, 1.09-1.44, respectively) compared with luteal GnRH agonist. Analysis of differences in the factors related to EP in luteal GnRH agonist versus GnRH antagonist protocols indicated that diminished ovarian reserve was associated with an increased risk of EP in luteal GnRH agonist but not in GnRH antagonist cycles.
CONCLUSION(S): The type of protocol used during ovarian hyperstimulation in fresh autologous cycles was associated with EP. This finding suggests a role for extrapituitary GnRH on the tubal and uterine environment during ovarian hyperstimulation treatment for IVF.
评估 2008 年至 2011 年期间在美国生殖技术协会(SART)报告的新鲜自体胚胎移植周期中不同卵巢刺激方案与体外受精(IVF)周期中异位妊娠(EP)的关系。
历史队列研究。
不适用。
无。
无。
所有导致新鲜宫内胚胎移植后临床妊娠的自体周期均包括在内,并根据方案描述了周期特征:黄体 GnRH 激动剂、GnRH 激动剂爆发、或 GnRH 拮抗剂。采用多变量逻辑回归分析方案类型与 EP 的关系。
在 136605 例临床妊娠中,2645 例(1.94%)为 EP。与 GnRH 激动剂爆发(2.1%)或黄体 GnRH 激动剂(1.6%)周期相比,GnRH 拮抗剂(2.4%)周期的 EP 更为常见。调整母体和治疗特征后,GnRH 拮抗剂和 GnRH 激动剂爆发方案与 EP 的发生风险增加相关(调整后的优势比[aOR] 1.52;95%置信区间[CI],1.39-1.65;和 aOR 1.25;95%CI,1.09-1.44),与黄体 GnRH 激动剂相比。黄体 GnRH 激动剂与 GnRH 拮抗剂方案中与 EP 相关的因素差异分析表明,卵巢储备减少与黄体 GnRH 激动剂而非 GnRH 拮抗剂周期中 EP 的风险增加相关。
新鲜自体周期卵巢刺激中使用的方案类型与 EP 相关。这一发现提示在 IVF 卵巢刺激治疗期间,垂体外 GnRH 对输卵管和子宫环境可能有作用。